Proteomic Analysis of Plasma and Urine for Efficacy Prediction Biomarkers of JAK Inhibitors Combined with Phototherapy in Vitiligo

The combination of Janus kinase (JAK) inhibitors and narrow-band ultraviolet B (NB-UVB) therapy is an effective treatment for vitiligo; however, reliable and convenient biomarkers for predicting treatment efficacy prior to therapy are currently lacking. The biomarker combination of pre-treatment plasma C-C motif chemokine ligand 5 and fibrinogen-like protein 1 levels, along with urine ezrin and glyceraldehyde 3-phosphate dehydrogenase levels, can predict the sensitivity to baricitinib combined with NB-UVB therapy in patients with vitiligo.